-
公开(公告)号:US12194086B2
公开(公告)日:2025-01-14
申请号:US16755257
申请日:2018-10-12
Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Inventor: David B. Weiner , Kar Muthumani , Sagar Kudchodkar
Abstract: Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.
-
公开(公告)号:US20240409618A1
公开(公告)日:2024-12-12
申请号:US18701492
申请日:2022-10-13
Applicant: David Weiner , Elizabeth Parzych , Trevor Smith , Ami Patel , Daniel Kulp , The Wistar Institute of Anatomy and Biology
Inventor: David Weiner , Elizabeth Parzych , Trevor Smith , Ami Patel , Daniel Kulp
Abstract: Disclosed herein are nucleic acid encoded Fc-modified antibodies and methods of use of the same for the treatment of diseases and disorders.
-
3.
公开(公告)号:US20240261388A1
公开(公告)日:2024-08-08
申请号:US18407958
申请日:2024-01-09
Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Inventor: David Weiner , Megan Wise
IPC: A61K39/21 , A61K39/00 , A61K39/02 , C07K14/005
CPC classification number: A61K39/21 , A61K39/02 , C07K14/005 , A61K2039/53 , A61K2039/54 , A61K2039/545 , C12N2740/16134 , C12N2740/16171
Abstract: The present invention relates to compositions comprising two or more DNA plasmids encoding consensus and transmitted founder HIV envelope glycoproteins which expressed and induce a potent immune response.
-
公开(公告)号:US20240246909A1
公开(公告)日:2024-07-25
申请号:US18408389
申请日:2024-01-09
Applicant: The Wistar Institute of Anatomy and Biology
Inventor: Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC: C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
CPC classification number: C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号:US20240221942A1
公开(公告)日:2024-07-04
申请号:US18392646
申请日:2023-12-21
Applicant: The Wistar Institute of Anatomy and Biology
Inventor: Noam Auslander , Abdurrahman Elbasir
Abstract: Systems and methods for identifying viral sequences in a subject of a species are provided. Sequence reads not associated with a reference genome of the species are obtained from a biological sample from the subject. At least a portion of each respective sequence read is encoded into a corresponding vector representing all or a portion of the sequence of the respective sequence read, thereby obtaining a plurality of vectors. Each sequence read is assigned a corresponding scalar model score by inputting a vector, in the plurality of vectors, corresponding to the sequence read into a model. Those sequence reads having a corresponding scalar model score that satisfies a first threshold score are selected as contig seeds. The plurality of sequence reads are aligned to these contig seeds through common k-mer sequences thereby forming a plurality of contigs which, in turn, are used to identify viral sequences in the subject.
-
公开(公告)号:US20240207202A1
公开(公告)日:2024-06-27
申请号:US18534114
申请日:2023-12-08
Applicant: The Wistar Institute of Anatomy and Biology
Inventor: Gao Zhang , Qin Liu , Dario Carlo Altieri , Meenhard Herlyn
IPC: A61K31/06 , A61K31/155 , A61K31/245 , A61K31/437 , A61K31/4439 , A61K31/5377 , A61K31/713 , A61K45/06 , A61P35/00 , C12Q1/6886 , G01N33/574
CPC classification number: A61K31/06 , A61K31/155 , A61K31/245 , A61K31/437 , A61K31/4439 , A61K31/5377 , A61K45/06 , A61P35/00 , C12Q1/6886 , G01N33/5743 , A61K31/713 , A61K2300/00 , C12Q2600/158 , G01N2800/44 , G01N2800/60 , G01N2800/7028
Abstract: Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.
-
7.
公开(公告)号:US20240165225A1
公开(公告)日:2024-05-23
申请号:US18344653
申请日:2023-06-29
Applicant: The Wistar Institute of Anatomy and Biology
Inventor: Jose R. Conejo-Garcia , Nikolaos A. Svoronos
IPC: A61K39/395 , A61K31/405 , A61K31/4245 , A61K45/06 , A61P35/04 , C07K16/28 , G01N33/74
CPC classification number: A61K39/3955 , A61K31/405 , A61K31/4245 , A61K45/06 , A61P35/04 , C07K16/2818 , G01N33/743 , G01N2333/723 , G01N2800/52
Abstract: Compositions and methods are provided for treating an estrogen receptor negative cancer in a subject with an elevated population of estrogen receptor positive myeloid-derived suppressor cells (MDSC's), including administering a therapeutically effective amount of an estrogen receptor antagonist to the subject in need thereof.
-
公开(公告)号:US20240139197A1
公开(公告)日:2024-05-02
申请号:US18483886
申请日:2023-10-10
Applicant: The Wistar Institute of Anatomy and Biology
Inventor: Rugang Zhang
IPC: A61K31/519 , A61K31/7105 , A61K38/21 , A61P35/00
CPC classification number: A61K31/519 , A61K31/7105 , A61K38/217 , A61P35/00
Abstract: Methods of treating cancer, promoting antigen presentation, or increasing CD8+ T cell infiltration in tumors by inhibiting KDMA5 are provided.
-
9.
公开(公告)号:US20240115680A1
公开(公告)日:2024-04-11
申请号:US18541798
申请日:2023-12-15
Applicant: The Trustees of the University of Pennsylvania , Inovio Pharmaceuticals, Inc. , The Wistar Institute of Anatomy and Biology
Inventor: David Weiner , Alfredo Perales Puchalt , Jian Yan , Anna Maria Slager
CPC classification number: A61K39/001102 , A61K38/1796 , A61K39/0011 , A61P35/00 , C07K14/723 , A61K2039/5256 , A61K2039/53 , A61K2039/572 , A61K2039/892
Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.
-
公开(公告)号:US20240105303A1
公开(公告)日:2024-03-28
申请号:US18469813
申请日:2023-09-19
Applicant: The Wistar Institute of Anatomy and Biology
Inventor: Noam Auslander , Andrew Patterson
IPC: G16H20/10
CPC classification number: G16H20/10
Abstract: Described are systems and methods of predicting a response to a medical treatment in a subject. The systems and methods include the steps of selecting a set of mutations within at least one biological process, training a set of classifiers from the set of selected mutations via a training dataset, determining the performance level of each classifier via a validation dataset, applying a subset of high-performance level classifiers from the validation dataset via a test dataset, and predicting the response to the medical treatment based on the test dataset.
-
-
-
-
-
-
-
-
-